# FDA 483 - Nanospectra Bioscience Inc - November 22, 2024

Source: https://www.keypedia.com/records/483/nanospectra-bioscience-inc/b77f3336-9379-482e-904a-357e9394faa2

> FDA 483 for Nanospectra Bioscience Inc on November 22, 2024. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Nanospectra Bioscience Inc
- Inspection Date: 2024-11-22
- Product Type: other
- Office Name: Dallas District Office
- Summary: An FDA inspection of Nanospectra Bioscience Inc, a sponsor in Houston, TX, revealed two significant observations. The firm failed to obtain updated financial disclosure information from participating investigators and did not ensure all investigators received consistent versions of the investigational plan. These issues indicate deficiencies in sponsor oversight of clinical investigations.

## Related Officers

- [CSO](https://www.keypedia.com/people/andrea-a-branche/9ffe9b53-7963-49a6-be4e-25e644f1759f)
- [Habacuc V. Barrera](https://www.keypedia.com/people/habacuc-v-barrera/d4149e5b-7424-4ab8-b7f1-23988c83d9cf)

Company: https://www.keypedia.com/companies/nanospectra-bioscience-inc/5d6f4fbc-ac19-4b9d-9adb-768339fbd110

Office: https://www.keypedia.com/offices/dallas-district-office/2d1ee9ae-c44c-4494-8186-a920a69b98f9